{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:21:46Z","timestamp":1772644906407,"version":"3.50.1"},"reference-count":29,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: This study aimed to compare test sensitivity for detecting aggressive prostate cancer and test specificity (measured by reduction in prostate biopsies) between algorithm-triage and standard systematic biopsy in elderly men with suspected prostate cancer.\nMethods: This randomised controlled trial enrolled men \u2265 70 years old suspected of prostate cancer and randomised them 1:1 to algorithm-triage or standard systematic biopsies. The algorithm arm used a 10-gene mRNA panel from urine and plasma samples, integrated with clinical characteristics and PSA measurements to predict prostate cancer with International Society of Urological Pathology grade group \u2265 2. Patient-reported outcomes measures were collected using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores or subdomains throughout a 24-month follow-up. ClinicalTrials.gov: NCT04079699.\nResults: A total of 202 men were included between October 2019 and September 2021. The study was terminated early due to algorithm underperformance. The algorithm-triage arm detected fewer indolent cancers (7.9% vs. 19%, absolute difference \u221210.9 percentage points, 95% confidence interval [CI]: \u221221.0 to \u22121.0 pp, P = 0.039) but also fewer clinically significant cancers (26% vs. 40%, absolute difference \u221213.9 percentage points, 95% CI: \u221227.6 to \u22120.1 pp, P = 0.051) compared to systematic biopsy. Patient-reported outcomes showed no significant between-group differences in FACT-P scores or subdomains throughout 24-month follow-up (differences 0.1\u20132.2 points, all P &gt; 0.05), indicating comparable quality of life.\nConclusion: The biomarker-based algorithm-triage reduced biopsy numbers but also detected fewer \u00adclinically significant prostate cancers. Quality of life was comparable between approaches.<\/jats:p>","DOI":"10.2340\/sju.v61.45464","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:42:10Z","timestamp":1772631730000},"page":"31-37","source":"Crossref","is-referenced-by-count":0,"title":["Plasma and urine biomarker algorithm versus systematic biopsy for prostate cancer detection in elderly men: a randomised trial with early termination for futility"],"prefix":"10.2340","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3266-1877","authenticated-orcid":false,"given":"Torben Br\u00f8chner","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1407-7976","authenticated-orcid":false,"given":"Charlotte Aaberg","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4443-8015","authenticated-orcid":false,"given":"Martin","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7661-9537","authenticated-orcid":false,"given":"Maher","family":"Albitar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-367X","authenticated-orcid":false,"given":"Louise Dorner","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-3299","authenticated-orcid":false,"given":"S\u00f8ren","family":"Feddersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-9568","authenticated-orcid":false,"given":"Lars","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7622-8402","authenticated-orcid":false,"given":"Mads Hvid","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"143403","doi-asserted-by":"crossref","unstructured":"Vickers A, O\u2019Brien F, Montorsi F, et al. Current policies on early detection of prostate cancer create overdiagnosis and inequity with min-imal benefit. BMJ. 2023;381:e071082. https:\/\/doi.org\/10.1136\/bmj-2022-071082","DOI":"10.1136\/bmj-2022-071082"},{"key":"143404","doi-asserted-by":"crossref","unstructured":"Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65:1046\u20131055. https:\/\/doi.org\/10.1016\/j.eururo.2013.12.062","DOI":"10.1016\/j.eururo.2013.12.062"},{"key":"143405","unstructured":"David MK, Leslie SW. Prostate-specific antigen. StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025 [cited 2025 Apr 22]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557495\/"},{"key":"143406","doi-asserted-by":"crossref","unstructured":"Ploussard G, de la Taille A. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection. Expert Rev Anticancer Ther. 2018;18: 1013\u20131020. https:\/\/doi.org\/10.1080\/14737140.2018.1502086","DOI":"10.1080\/14737140.2018.1502086"},{"key":"143407","doi-asserted-by":"crossref","unstructured":"Tosoian JJ, Zhang Y, Xiao L, et al. Development and validation of an 18-gene urine test for high-grade prostate cancer. JAMA Oncol. 2024;10:726\u2013736. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0455","DOI":"10.1001\/jamaoncol.2024.0455"},{"key":"143408","doi-asserted-by":"crossref","unstructured":"Hendriks RJ, van der Leest MMG, Isra\u00ebl B, et al. Clinical use of the SelectMDx urinary-biomarker test with or without mpMRI in prostate cancer diagnosis: a prospective, multicenter study in biopsy-na\u00efve men. Prostate Cancer Prostatic Dis. 2021;24:1110\u20131119. https:\/\/doi.org\/10.1038\/s41391-021-00367-8","DOI":"10.1038\/s41391-021-00367-8"},{"key":"143409","doi-asserted-by":"crossref","unstructured":"Margolis E, Brown G, Partin A, et al. Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies. Prostate Cancer Prostatic Dis. 2022;25:296\u2013301. https:\/\/doi.org\/10.1038\/s41391-021-00456-8","DOI":"10.1038\/s41391-021-00456-8"},{"key":"143410","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Vickers A, Assel M, et al. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68:139\u2013146. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.010","DOI":"10.1016\/j.eururo.2014.08.010"},{"key":"143411","doi-asserted-by":"crossref","unstructured":"Wagaskar VG, Sobotka S, Ratnani P, et al. A 4K score\/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer. Cancer Rep (Hoboken). 2021;4:e1357. https:\/\/doi.org\/10.1002\/cnr2.1357","DOI":"10.1002\/cnr2.1357"},{"key":"143412","doi-asserted-by":"crossref","unstructured":"Albitar M, Ma W, Lund L, et al. A multi-center prospective study to validate an algorithm using urine and plasma biomarkers for predicting Gleason \u22653+4 prostate cancer on biopsy. J Cancer. 2017;8:2554\u20132560. https:\/\/doi.org\/10.7150\/jca.20031","DOI":"10.7150\/jca.20031"},{"key":"143413","doi-asserted-by":"crossref","unstructured":"Albitar M, Ma W, Lund L, et al. Predicting prostate biopsy results using a panel of plasma and urine biomarkers combined in a scoring system. J Cancer. 2016;7:297\u2013303. https:\/\/doi.org\/10.7150\/jca.12771","DOI":"10.7150\/jca.12771"},{"key":"143414","doi-asserted-by":"crossref","unstructured":"Ma W, Diep K, Fritsche HA, et al. Diagnostic and prognostic scoring system for prostate cancer using urine and plasma biomarkers. Genet Test Mol Biomarkers. 2014;18:156\u2013163. https:\/\/doi.org\/10.1089\/gtmb.2013.0424","DOI":"10.1089\/gtmb.2013.0424"},{"key":"143415","doi-asserted-by":"crossref","unstructured":"Poulsen MH, Feddersen S, Albitar M, et al. A prospective study of a urine and plasma biomarker test for the prediction of gleason \u2265 3 + 4 prostate cancer in a mixed cohort. Scand J Urol. 2020;54:323\u2013327. https:\/\/doi.org\/10.1080\/21681805.2020.1782979","DOI":"10.1080\/21681805.2020.1782979"},{"key":"143416","doi-asserted-by":"crossref","unstructured":"Pedersen TB, Poulsen MH, Lund M, et al. Prospective validation study of a combined urine and plasma test for predicting high-grade pros-tate cancer in biopsy na\u00efve men. Scand J Urol. 2025;60:8\u201313. https:\/\/doi.org\/10.2340\/sju.v60.42752","DOI":"10.2340\/sju.v60.42752"},{"key":"143417","doi-asserted-by":"crossref","unstructured":"Brewster DH, Fischbacher CM, Nolan J, et al. Risk of hospitalization and death following prostate biopsy in Scotland. Public Health. 2017;142:102\u2013110. https:\/\/doi.org\/10.1016\/j.puhe.2016.10.006","DOI":"10.1016\/j.puhe.2016.10.006"},{"key":"143418","doi-asserted-by":"crossref","unstructured":"Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095\u20132101. https:\/\/doi.org\/10.1001\/jama.293.17.2095","DOI":"10.1001\/jama.293.17.2095"},{"key":"143419","doi-asserted-by":"crossref","unstructured":"Thomsen FF, Garmo H, Egevad L, et al. Temporal trend in risk of prostate cancer death in men with favourable-risk prostate cancer. Scand J Urol. 2024;59:76\u201383. https:\/\/doi.org\/10.2340\/sju.v59.34015","DOI":"10.2340\/sju.v59.34015"},{"key":"143420","doi-asserted-by":"crossref","unstructured":"Stranne J. 2023\/2024 update of the national prostate cancer guidelines in Sweden. Scand J Urol. 2024;59:210\u2013211. https:\/\/doi.org\/10.2340\/sju.v59.42656","DOI":"10.2340\/sju.v59.42656"},{"key":"143421","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"143422","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u2013381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"143423","doi-asserted-by":"crossref","unstructured":"Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials. 1997;18:530\u2013545; discussion 546\u2013549. https:\/\/doi.org\/10.1016\/S0197-2456(97)00008-1","DOI":"10.1016\/S0197-2456(97)00008-1"},{"key":"143424","doi-asserted-by":"crossref","unstructured":"Machin D, Campbell MJ, Tan S-B. Sample size tables for clinical \u00adstudies. 3rd ed. Chichester, UK: Wiley; 2009.","DOI":"10.1002\/9781444300710"},{"key":"143425","doi-asserted-by":"crossref","unstructured":"Lazarovich A, Vigneswaran H, Palsdottir T, et al. A comparison of Stockholm3, serum biomarkers, and risk calculators to predict prostate cancer in a racially and ethnically diverse cohort: evaluation of the Stockholm3 multiethnic SEPTA Trial. J Urol. 2025;213:590\u2013599. https:\/\/doi.org\/10.1097\/JU.0000000000004437","DOI":"10.1097\/JU.0000000000004437"},{"key":"143426","doi-asserted-by":"crossref","unstructured":"Nordstr\u00f6m T, Discacciati A, Bergman M, et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol [Internet]. 2021;22:1240\u20131249. https:\/\/doi.org\/10.1016\/S1470-2045(21)00348-X","DOI":"10.1016\/S1470-2045(21)00348-X"},{"key":"143427","doi-asserted-by":"crossref","unstructured":"Vigneswaran HT, Eklund M, Discacciati A, et al. Stockholm3 in a multiethnic cohort for Prostate Cancer Detection (SEPTA): a prospective multicentered trial. J Clin Oncol. 2024;42:3806\u20133816. https:\/\/doi.org\/10.1200\/JCO.24.00152","DOI":"10.1200\/JCO.24.00152"},{"key":"143428","doi-asserted-by":"crossref","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PRO-MIS): a paired validating confirmatory study. Lancet. 2017;389:815\u2013822. https:\/\/doi.org\/10.1016\/S0140-6736(16)32401-1","DOI":"10.1016\/S0140-6736(16)32401-1"},{"key":"143429","doi-asserted-by":"crossref","unstructured":"Ng ABCD, Asif A, Agarwal R, et al. Biparametric vs multiparametric MRI for prostate cancer diagnosis: the PRIME diagnostic clinical trial. JAMA [Internet]. 2025;334:1170\u20131179. https:\/\/doi.org\/10.1001\/jama.2025.13722","DOI":"10.1001\/jama.2025.13722"},{"key":"143430","doi-asserted-by":"crossref","unstructured":"Shao L, Liang C, Yan Y, et al. An MRI-pathology foundation model for noninvasive diagnosis and grading of prostate cancer. Nat Cancer. 2025;6:1621\u20131637. https:\/\/doi.org\/10.1038\/s43018-025-01041-x","DOI":"10.1038\/s43018-025-01041-x"},{"key":"143431","doi-asserted-by":"crossref","unstructured":"Shankar PR, Ellimoottil C, George AK, et al. Testing-related health impact of transrectal and transperineal prostate biopsy as assessed by health utilities. J Urol. 2021;206:1403\u20131410. https:\/\/doi.org\/10.1097\/JU.0000000000002118","DOI":"10.1097\/JU.0000000000002118"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45464\/53070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45464\/53070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:42:16Z","timestamp":1772631736000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.45464","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]}}}